BD announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY investigational device exemption (IDE) ...

BD (NYSE: BDX) today announced that it completed enrollment in the iliac artery patient cohort in its pivotal AGILITY study.

A bioadaptor implant adaptable to vessel physiology was linked to less target lesion failure and target vessel failure ...

Becton Dickinson (BDX) announced full enrollment of the iliac artery patient cohort in its AGILITY investigational device ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device ...

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.